Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 572 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR Professor Eithne Costello: On the road to early detection November 12, 2021 An unexpected find: clues about the genetics of children’s cancer found... April 6, 2021 Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients... February 25, 2025 FDA Authorizes Blood Test for Assessing Risk of Hereditary Cancers November 2, 2023 Load more HOT NEWS Truck Driver Saves People From Bus Fire On Christmas Eve Why Have Thyroid Cancer Diagnoses Spiked for US Women? Safety Analysis Shows that Durvalumab Treatment After SBRT Is Feasible in... New Research in Treating Non-Small Cell Lung Cancer: 2022 North America...
